- Home
- WEA vs SGMO Comparison
WEA vs SGMO Comparison
Compare WEA & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEA
- SGMO
- Stock Information
- Founded
- WEA 2002
- SGMO 1995
- Country
- WEA United States
- SGMO United States
- Employees
- WEA N/A
- SGMO N/A
- Industry
- WEA Trusts Except Educational Religious and Charitable
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WEA Finance
- SGMO Health Care
- Exchange
- WEA Nasdaq
- SGMO Nasdaq
- Market Cap
- WEA 129.0M
- SGMO 122.8M
- IPO Year
- WEA N/A
- SGMO 2000
- Fundamental
- Price
- WEA $10.89
- SGMO $0.54
- Analyst Decision
- WEA
- SGMO Buy
- Analyst Count
- WEA 0
- SGMO 6
- Target Price
- WEA N/A
- SGMO $4.50
- AVG Volume (30 Days)
- WEA 46.1K
- SGMO 6.0M
- Earning Date
- WEA 01-01-0001
- SGMO 08-05-2025
- Dividend Yield
- WEA 7.87%
- SGMO N/A
- EPS Growth
- WEA N/A
- SGMO N/A
- EPS
- WEA N/A
- SGMO N/A
- Revenue
- WEA N/A
- SGMO $63,756,000.00
- Revenue This Year
- WEA N/A
- SGMO N/A
- Revenue Next Year
- WEA N/A
- SGMO N/A
- P/E Ratio
- WEA N/A
- SGMO N/A
- Revenue Growth
- WEA N/A
- SGMO 239.92
- 52 Week Low
- WEA $9.60
- SGMO $0.30
- 52 Week High
- WEA $11.29
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- WEA 63.78
- SGMO 51.37
- Support Level
- WEA $10.77
- SGMO $0.41
- Resistance Level
- WEA $10.84
- SGMO $0.61
- Average True Range (ATR)
- WEA 0.11
- SGMO 0.05
- MACD
- WEA 0.01
- SGMO 0.01
- Stochastic Oscillator
- WEA 57.29
- SGMO 62.50
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.